UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stock Position in argenx SE (NASDAQ:ARGX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 50.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,425 shares of the company's stock after selling 20,417 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's holdings in argenx were worth $12,561,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of ARGX. GeoWealth Management LLC grew its stake in shares of argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after acquiring an additional 18 shares during the last quarter. Whipplewood Advisors LLC purchased a new position in shares of argenx in the 4th quarter valued at approximately $37,000. Global Retirement Partners LLC raised its position in shares of argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after purchasing an additional 48 shares during the last quarter. FIL Ltd purchased a new position in shares of argenx in the 4th quarter valued at approximately $38,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of argenx in the 4th quarter valued at approximately $38,000. 60.32% of the stock is currently owned by institutional investors.

argenx Price Performance

Shares of ARGX traded up $6.83 during mid-day trading on Monday, reaching $580.09. The stock had a trading volume of 181,804 shares, compared to its average volume of 322,925. argenx SE has a 52-week low of $368.57 and a 52-week high of $678.21. The business's fifty day moving average is $586.57 and its 200 day moving average is $612.64. The firm has a market cap of $35.42 billion, a price-to-earnings ratio of -659.19 and a beta of 0.57.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. The business had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, sell-side analysts anticipate that argenx SE will post 3.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ARGX has been the subject of a number of recent research reports. William Blair reissued an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft raised shares of argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. Robert W. Baird raised shares of argenx from a "neutral" rating to an "outperform" rating and set a $680.00 price target for the company in a research report on Tuesday, May 13th. Citigroup reissued a "buy" rating on shares of argenx in a report on Wednesday, May 21st. Finally, JMP Securities set a $699.00 target price on shares of argenx in a report on Wednesday, May 14th. One research analyst has rated the stock with a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, argenx currently has a consensus rating of "Buy" and an average target price of $709.18.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.